New Leadership Appointments: Allogenica appoints Tobias Abel, PhD, formerly with Sangamo Therapeutics, as Chief Scientific Officer and Aymeric Bordet, an expert in overseeing financial strategies from seed to Series B rounds, as Chief Financial Officer.
Expertise for Growth: These additions are aimed at accelerating Allogenica’s groundbreaking cell therapy programs.
Lyon, France – November 19, 2024 – Allogenica, a preclinical-stage biotech company developing therapeutic programs on a breakthrough cell therapy platform focused on cancer, rare diseases, and autoimmune disorders, is excited to announce the addition of Tobias Abel, PhD, as Chief Scientific Officer (CSO), and Aymeric Bordet as Chief Financial Officer (CFO).
Commenting on these appointments, Dr. Inna Menkova, CEO of Allogenica, said: “We are very pleased to welcome Dr. Tobias Abel and Mr. Aymeric Bordet to our management team. Tobias’ extensive experience in cell therapy and gene technology will be instrumental in advancing our key programs. Mr. Bordet brings a wealth of financial expertise, having led significant operations and expansions in the biotech sector. His expertise in overseeing financial strategies from seed to Series B rounds will be crucial as Allogenica leverages its non-dilutive and privatefunding to drive growth and innovation. With the addition of these new members to our team, we are well-positioned to advance our mission and achieve our ambitious goals in revolutionizing patient care.”
Dr. Tobias Abel – Chief Scientific Officer
Dr. Tobias Abel, a distinguished life sciences executive, joins Allogenica as CSO. With over 15 years of experience in biotechnology and gene therapy, Dr. Abel has a proven track record of advancing cell therapies from bench to bedside. In his previous role as Associate Director of Translational Biotech at Sangamo Therapeutics, he led the development of innovative gene and cell therapies, overcoming critical challenges and accelerating the transition of preclinical projects to the clinic.
His strategic vision and technical acumen will be instrumental in advancing the company’s key programs, notably in solid tumors, which represent a significant unmet medical need.
Aymeric Bordet –Chief Financial Officer
Aymeric Bordet joins Allogenica as Part-Time CFO, bringing extensive experience in financial management and strategic consulting across fintech, CRO, and biotech sectors. Known for his role in managing significant financial operations and expansions, Mr. Bordet has held several part-time CFO positions and was awarded the 2022 CFO Trophy for the Auvergne Rhône-Alpes region.
His expertise in overseeing financial strategies from seed funding to Series B rounds will be crucial as Allogenica leverages its non-dilutive and private funding to drive growth and innovation.
